Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

This Article Full Text Full Text (PDF, 5572K) PPT slides of all figures Supplemental Material Index Related biobytes podcast Alert me when this article is cited Citation Map Services Email this article Similar articles in this journal Similar articles in PubMed Alert me to new content in the JEM Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Quezada, S. A. Articles by Allison, J. P. Search for Related Content PubMed PubMed Citation Articles by Quezada, S. A. Articles by Allison, J. P. Related Collections Related In this Issue article Social Bookmarking                            What's this?

¹ Howard Hughes Medical Institute and the Ludwig Center for Cancer Immunotherapy, Department of Immunology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021
² Howard Hughes Medical Institute, Skirball Institute of Biomolecular Medicine, New York University School of Medicine, New York, NY 10016

CORRESPONDENCE James P. Allison: allisonj{at}mskcc.org

Interference with inhibitory immunological checkpoints controlling T cell activation provides new opportunities to augment cancer immunotherapies. Whereas cytotoxic T lymphocyte–associated antigen-4 blockade has shown promising preclinical and clinical results, therapeutic CD4⁺CD25⁺ T reg cell depletion has failed to consistently enhance immune-based therapies. Using B16/BL6, a transplantable murine melanoma model, we show a dichotomy between the effects of T reg cell depletion on tumor rejection dependent on whether depletion occurs before (prophylactic) or after (therapeutic) tumor engraftment. Failure to promote rejection with therapeutic depletion is not related to lack of T reg cell depletion, to elimination of CD25⁺ effector T cells, or to a failure to enhance systemic antitumor T cell responses, but correlates with failure of effector cells to infiltrate the tumor and increase the intratumor ratio of effector T cell/T reg cell. Finally, systemic antitumor responses generated upon therapeutic T reg cell depletion are significantly stronger than those generated in the presence of T reg cells, and are capable of eliciting rejection of established tumors after transfer into immunoablated recipients receiving combination immunotherapy. The data demonstrate a dissociation between measurable systemic responses and tumor rejection during CD25-directed T reg cell depletion, and suggest an alternative, clinically applicable strategy for the treatment of established tumors.

S.A. Quezada and K.S. Peggs contributed efqually to this paper.

K.S. Peggs' present address is UCL Cancer Institute, University College London, WC1E 6BT London, England, UK.

© 2008 Quezada et al. This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.jem.org/misc/terms.shtml). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

Related In this Issue article

Large tumors too slippery for T cells?

Hema Bashyam
J. Exp. Med. 2008 205: 1945. [Full Text] [PDF]

This article has been cited by other articles:

• Zhou, Q., Bucher, C., Munger, M. E., Highfill, S. L., Tolar, J., Munn, D. H., Levine, B. L., Riddle, M., June, C. H., Vallera, D. A., Weigel, B. J., Blazar, B. R. (2009). Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia. Blood 114: 3793-3802 [Abstract] [Full Text]  
• Petrausch, U., Jensen, S. M., Twitty, C., Poehlein, C. H., Haley, D. P., Walker, E. B., Fox, B. A. (2009). Disruption of TGF-{beta} Signaling Prevents the Generation of Tumor-Sensitized Regulatory T Cells and Facilitates Therapeutic Antitumor Immunity. J. Immunol. 183: 3682-3689 [Abstract] [Full Text]  
• Peggs, K. S., Quezada, S. A., Chambers, C. A., Korman, A. J., Allison, J. P. (2009). Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. JEM 206: 1717-1725 [Abstract] [Full Text]  
• Jackaman, C., Cornwall, S., Lew, A. M., Zhan, Y., Robinson, B. W. S., Nelson, D. J. (2009). Local effector failure in mesothelioma is not mediated by CD4+ CD25+ T-regulator cells. Eur Respir J 34: 162-175 [Abstract] [Full Text]  
• Sharma, M. D., Hou, D.-Y., Liu, Y., Koni, P. A., Metz, R., Chandler, P., Mellor, A. L., He, Y., Munn, D. H. (2009). Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes. Blood 113: 6102-6111 [Abstract] [Full Text]  
• Liu, Y., Peng, Y., Mi, M., Guevara-Patino, J., Munn, D. H., Fu, N., He, Y. (2009). Lentivector Immunization Stimulates Potent CD8 T Cell Responses against Melanoma Self-Antigen Tyrosinase-Related Protein 1 and Generates Antitumor Immunity in Mice. J. Immunol. 182: 5960-5969 [Abstract] [Full Text]  
• Gerner, M. Y., Mescher, M. F. (2009). Antigen Processing and MHC-II Presentation by Dermal and Tumor-Infiltrating Dendritic Cells. J. Immunol. 182: 2726-2737 [Abstract] [Full Text]  
• Schreiber, T. H., Deyev, V. V., Rosenblatt, J. D., Podack, E. R. (2009). Tumor-Induced Suppression of CTL Expansion and Subjugation by gp96-Ig Vaccination. Cancer Res. 69: 2026-2033 [Abstract] [Full Text]  

Home | Help | Feedback | Subscriptions | Archive | Search

TABLE OF CONTENTS